Frontline Immunotherapy and Molecular Precision in Advanced Endometrial Cancer

The management of endometrial cancer has transitioned from a purely histopathological model to a sophisticated framework based on molecular precision. This shift is primarily centered on the integration of immune checkpoint inhibitors. Consequently, clinicians have observed a radical change in standards for different genomic subsets. For patients with mismatch repair deficient or microsatellite instability-high tumors, frontline immunotherapy endometrial cancer strategies have officially moved from late-line options to the primary standard of care.

Standardizing Frontline Immunotherapy Endometrial Cancer Strategies

Landmark results from the RUBY and NRG-GY018 trials have redefined the first-line setting. These studies demonstrate that combining dostarlimab or pembrolizumab with platinum-based chemotherapy significantly improves survival in patients with untreated advanced disease. Furthermore, the updated long-term data from these trials continue to show a sustained benefit across molecular subgroups. While the most dramatic responses occur in mismatch repair deficient populations, researchers are also identifying meaningful gains in proficient cohorts.

Overcoming Immune-Cold Reprogramming in pMMR Tumors

Mismatch repair proficient (pMMR) tumors represent the majority of cases and often present an immune-cold microenvironment. Therefore, overcoming resistance in these patients requires innovative combination strategies. The KEYNOTE-775 trial demonstrated that combining anti-angiogenic agents like lenvatinib with immune checkpoint inhibitors can enhance therapeutic efficacy. Additionally, data from the DUO-E study suggest that incorporating DNA damage response inhibitors may improve outcomes in pMMR populations. Consequently, the use of antibody-drug conjugates and liquid biopsy monitoring is helping personalize these precision treatments even further.

Frequently Asked Questions

Which trials supported the use of frontline immunotherapy in endometrial cancer?

The RUBY and NRG-GY018 trials are the primary studies that established the efficacy of adding dostarlimab or pembrolizumab to standard chemotherapy for frontline treatment.

What is the role of molecular subtypes in choosing therapy?

Molecular classification identifies patients with dMMR/MSI-H status who are highly responsive to immunotherapy. It also helps identify pMMR patients who may benefit more from combination therapies involving anti-angiogenic or DNA repair inhibitors.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Lin PH et al. Frontline immunotherapy and immune cold reprogramming across molecular subtypes of advanced endometrial cancer. Cancer Lett. 2026 Jun 04. doi: undefined. PMID: 42241805.


2. Eskander RN et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023.


3. Mirza MR et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023.


4. Makker V et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022.